Photoof Erman Akkus from X
May 31, 2024, 15:03
CheckMate 648 review by Erman Akkus
Erman Akkus, Medical Oncologist at Ankara University, shared on X:
“First line Nivolumab plus ChT / Nivolumab plus ipilimumab vs only ChT in advanced esophageal SCC.
CheckMate 648, 29-month follow-up: .
- Both IO combination provided better OS
- Nivo-ChT vs ChT
- PD-L1 ≥1%: HR=0.59 (0.46–0.76)
- Overall population: HR = 0.78 (0.65–0.93)
- Nivo-Ipi vs ChT PD-L1 ≥1%: HR = 0.62 (0.48–0.80)
- Overall population: HR = 0.77 (0.65–0.92)
- Grade 3–4 AEs: 49% vs 32% vs 36%”
Source: Erman Akkus/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 11:30
Dec 21, 2024, 11:25
Dec 21, 2024, 11:18
Dec 21, 2024, 11:12
Dec 21, 2024, 11:06
Dec 21, 2024, 10:38